rosiglitazone has been researched along with Osteoporosis, Postmenopausal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzpatrick, LA; Guldberg, RE; Hoffman, SJ; Jolette, J; Kumar, S; Mansell, P; Samadfam, R; Smith, SY | 1 |
| Fukui, M; Hinoi, E; Ito, Y; Kitao, T; Kubo, M; Shirahase, H; Yoneda, Y | 1 |
| Berberoglu, Z; Demirag, NG; Yazici, AC | 1 |
| Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M | 1 |
1 trial(s) available for rosiglitazone and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2010 |
3 other study(ies) available for rosiglitazone and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors; X-Ray Microtomography | 2013 |
Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
Topics: Adipocytes; Animals; Bone Density; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Isoquinolines; Osteoblasts; Osteoporosis, Postmenopausal; Ovariectomy; Oxazoles; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Inbred F344; Receptor, Insulin; Risk; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |